Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Innoviva launched Nortiva Bio, a wholly-owned subsidiary focused on developing long-acting oral medicines using the proprietary LYNX drug delivery platform. Nortiva's lead program is a once-monthly oral contraceptive supported by a $5 million grant from the Gates Foundation, building on preclinical proof of concept.
Key figures
- Lead asset
- monthly oral contraceptive
- Grant amount
- $5 million
- Platform patents
- more than 50
- Platform phase validation
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.